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Figure S1. Structure of compound 21 in the solid state in two different orientations 
S-3 
 
X-ray Crystal Structure Analysis of Compound 21: C23 H29 N O5 S, Mr = 431.53  g · mol
-1, colorless prism, 
crystal size 0.258 x 0.199 x 0.060 mm3, monoclinic, space group C2, a = 20.625(3) Å, b = 7.8102(11) Å, c = 
14.940(2) Å, β = 102.870(3)°, V = 2346.3(6) Å3, T = 100 K, Z = 4, Dcalc = 1.222  g · cm
3,  = 0.71073 Å, (Mo-
K) = 0.170 mm
-1, Gaussian absorption correction (Tmin = 0.97, Tmax = 0.99), Bruker AXS Enraf-Nonius 
KappaCCD diffractometer, 3.795 <  < 30.746°, 33814 measured reflections, 7294 independent 
reflections, 6008 reflections with I > 2(I), Rint = 0.038. The structure was solved by direct methods and 
refined by full-matrix least-squares against F2 to R1 = 0.037 [I > 2(I)], wR2 = 0.092, 273 parameters, H 
atoms riding, S = 1.020, residual electron density 0.2 / -0.2 e Å-3. CCDC 1454695 
 
Experimental details and characterization data 
General. Unless stated otherwise, all reactions were carried out in flame-dried glassware using 
anhydrous solvents under argon. The solvents were purified by distillation over the following drying 
agents and were transferred under argon: THF, Et2O (Mg/anthracene), CH2Cl2, toluene (Na/K), MeOH 
(Mg, stored over MS 3 Å); DMF, DMSO, Et3N and pyridine were dried by an adsorption solvent 
purification system based on molecular sieves; anhydrous (99.9%) cyclopentyl methyl ether (CPME) 
purchased from Aldrich was kept in a flame-dried Schlenk flask containing MS 4 Å under argon. Thin layer 
chromatography (TLC): Macherey-Nagel precoated plates (POLYGRAM®SIL/UV254); Preparative TLC: 
Macherey-Nagel precoated plates (SIL G-100 UV 254; silica gel layer: 1.0 mm); Flash chromatography: 
Merck silica gel 60 (40–63 μm) with predistilled or HPLC grade solvents; Celite was dried at 170 oC for 
48 h under high vacuum (1 × 10-3 mbar) and stored under argon. NMR: Spectra were recorded on Bruker 
DPX 300, AV 400, AV 500 or AVIII 600 spectrometers in the solvents indicated; chemical shifts (δ) are 
given in ppm relative to TMS, coupling constants (J) in Hz. The solvent signals were used as references 
and the chemical shifts converted to the TMS scale (CDCl3: δC = 77.0 ppm; residual CHCl3 in CDCl3: δH = 
7.26 ppm; C6D6: δC = 128.06 ppm; residual C6D5H: δH = 7.16 ppm). IR: Spectrum One (Perkin-Elmer) 
spectrometer, wavenumbers (𝜈) in cm-1. MS (EI): Finnigan MAT 8200 (70 eV), ESI-MS: ESQ3000 (Bruker), 
accurate mass determinations: Bruker APEX III FTMS (7 T magnet) or Mat 95 (Finnigan). Optical rotations 
( 20
D][  =) were measured with a Perkin-Elmer Model 343 polarimeter. LC-MS analyses were conducted on 
a Shimadzu LC-MS 2020 instrument (pumps LC-20AD, autosampler SIL-20AC, column oven CTO-20AC, 
diode array detector SPD-M20A, controller CBM-20A, ESI detector and software Labsolutions) with a 
ZORBAX Eclipse Plus column (C18 1.8 μm, 3.0 or 4.6 mm ID × 50 mm (Agilent)) or a YMC-Pack Pro C18 
column (S-5 μm, 120 Å, 2.1 mm ID × 150 mm). A binary gradient of MeCN or MeOH in water, aq. 
triethylammonium acetate buffer (10 mmol, pH 8) or aq. trifluoroacetatic acid buffer (0.1 %) were used 
as eluents at a flow rate of 0.2 mL/min (2.1 mm ID), 0.5 mL/min (3.0 mm ID) or 0.8 mL/min (4.6 mm ID). 
The oven temperature was kept at 35 °C and the detection wave length at 228 nm or 258 nm. Conditions 
for each compound are specified below. Chiral HPLC analyses were conducted on a Shimadzu LC 20 
instrument (pumps LC-20AB, autosampler SIL-20AC, column oven CTO-20AC, diode array detector SPD-
M20A, controller CBM-20A, and software Labsolutions) with a Daicel Chiralpak IC-3 column (4.6 mm × 
150 mm). Unless stated otherwise, all commercially available compounds (Alfa Aesar, Aldrich, TCI, Strem 
Chemicals) were used as received.  
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tert-Butyl (Z)-3-iodoacrylate (12).[1] tert-Butyl propiolate (15.4 mmol, 1.94 g) was added to a solution of 
NaI (23.5 mmol, 3.53 g) in acetic acid (9 mL) and the resulting mixture was stirred at 70 oC for 
16 h. The mixture was cooled to room temperature before it was diluted with water (30 mL) 
and diethyl ether (30 mL). The aqueous phase was extracted with Et2O (4 × 30 mL). The 
combined extracts were neutralized with aq. KOH (3 M), washed with brine (50 mL), dried over MgSO4, 
filtered and concentrated in vacuum. Purification of the residue on silica gel by flash chromatography 
(hexane/EtOAc = 100/1 to 50/1) gave the product as a pale yellow oil (3.17 g, 81%). 1H NMR (400 MHz, 
CDCl3): δ = 7.30 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 8.8 Hz, 1H), 1.52 (s, 9H). 
13C NMR (100 MHz, CDCl3): δ = 
163.9, 131.3, 92.9, 81.8, 28.1. IR (film, cm-1): 3003, 2978, 2933, 1721, 1708, 1596, 1368, 1323, 1215, 1139, 
946, 810, 528. MS (EI): m/z (%) 254 (12), 198 (100), 181 (93), 153 (17), 127 (19), 71 (7), 56 (69), 41 (41), 
29 (12). HRMS (ESI): m/z: calcd for C7H11O2INa [M +Na
+]: 276.96960, found: 276.96940. 
 tert-Butyl (S, Z)-7-hydroxyoct-2-en-4-ynoate (13). Step 1: (S)-2-Methyloxirane (49.6 mmol, 3.47 mL) was 
added dropwise at 0 °C to a suspension of lithium acetylide-ethylene diamine 
complex (54.7 mmol, 5.6 g, 90%) in DMSO (50 mL). Once the addition was 
complete, the mixture was stirred at RT for 15 h. The mixture was poured onto 
ice and the resulting solution was extracted with Et2O (4 × 50 mL). The combined organic layers were 
washed with brine, dried over MgSO4 and concentrated in vacuo to afford alkyne 10 as a yellow volatile 
oil, which was used in the next step without further purification.[2]  
Step 2: tert-Butyl (Z)-3-iodoacrylate (12) (5.09 mmol, 1.29 g) and the crude 10 (6.2 mmol, 558.7 mg, 94% 
in Et2O) were added successively to a stirred solution of CuI (0.28 mmol, 54.2 mg) and Pd(PPh3)4 (0.25 
mmol, 288 mg) in Et3N (20 mL). Stirring was continued in a sealed Schlenk tube at 30 
oC for 70 h. The 
mixture was diluted with tert-butyl methyl ether (20 mL) and the reaction was quenched with H2O (15 
mL). The aqueous layer was extracted with tert-butyl methyl ether (3 × 30 mL), and the combined 
organic phases were dried over MgSO4, filtered, and concentrated. The crude material was purified by 
flash chromatography on silica gel (hexane/EtOAc = 20/1 to 10/1) to yield the title compound as a yellow 
oil (992.2 mg, 93%). 20
D][  = +49.2 (c = 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3): δ = 6.05 (s, 2H), 4.09-4.00 
(m, 1H), 3.82 (d, J = 4.4 Hz, 1H), 2.61 (dd, J = 16.8, 4.0 Hz, 1H), 2.47 (dd, J = 16.8, 7.6 Hz, 1H), 1.48 (s, 9H), 
1.28 (d, J = 6.0 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 164.4, 130.4, 122.8, 100.0, 81.1, 80.9, 66.2, 30.8, 
28.1, 22.1. IR (film, cm-1): 3461, 2976, 2931, 2208, 1702, 1605, 1480, 1456, 1408, 1367, 1303, 1237, 1210, 
1147, 1084, 1060, 1029, 959, 938, 869, 856, 817, 759, 728, 541, 477, 444, 429. MS (EI): m/z (%) 154 (6), 
137 (21), 110 (100), 92 (19), 82 (64), 65 (15), 57 (63), 45 (31), 41 (26), 39 (17), 29 (16). HRMS (ESI): m/z: 
calcd for: C12H18O3Na [M+Na
+]: 233.11481, found: 233.11480.  
(S)-6-(2-Hydroxypropyl)-2H-pyran-2-one (14). [(Xphos)AuNTf2] (0.039 mmol, 37.1 mg) was added to a 
solution of compound 13 (3.5 mmol, 743 mg) in MeNO2 (5.7 mL) and HOAc (1.4 mL) 
and the resulting mixture was stirred for 23 h. The mixture was adsorbed on silica 
which was loaded on top of a flash column filled with silica, and the product was 
eluted with hexane/EtOAc (4/1 to 1/3). The desired product was obtained as a yellow oil (484 mg, 89%). 
20
D][  = +121.8 (c = 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3): δ = 7.28 (dd, J = 9.6, 6.8 Hz, 1H), 6.17 (dd, J = 
9.2, 0.89 Hz, 1H), 6.09 (dt, J = 6.8, 0.8 Hz, 1H), 4.30-4.17 (m, 1H), 2.66-2.53 (m, 2H), 2.38 (br s, 1H), 1.27 
(d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 163.4, 162.9, 143.8, 113.5, 104.7, 65.4, 43.3, 23.3. IR 
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(film, cm-1): 3412, 2974, 2934, 1725, 1633, 1558, 1384, 1174, 1103, 940, 914, 804, 726, 697, 544. MS (EI): 
m/z (%) 154 (10), 110 (100), 95 (44), 82 (33), 68 (5), 54 (7), 45 (30), 39 (68), 27 (12). HRMS (EI): m/z: calcd 
for: C8H10O3 [M]: 154.06300, found: 154.06284. 
(S)-1-(2-Oxo-2H-pyran-6-yl)propan-2-yl pent-4-enoate (15). 2,4,6-Trichlorobenzoyl chloride  (4.8 mmol, 
0.75 mL) was slowly added to a stirred solution of 4-pentenoic acid (4.8 mmol, 481 
mg) and Et3N (4.8 mmol, 0.66 mL) in toluene (60 mL) at 0 
oC. After stirring at RT for 
1.5 h, the mixture was cooled to 0 oC and DMAP (7.2 mmol, 886.8 mg) was added, 
followed by a solution of compound 14 (4 mmol, 617.8 mg) in toluene (20 mL) (the 
flask was rinsed with 2 × 2.5 mL of THF). After stirring for 1 h at RT, the reaction was quenched with 
water (20 mL). The aqueous phase was extracted with EtOAc (3 × 30 mL) and the combined extracts 
were dried over MgSO4, filtered and concentrated. The residue was purified by flash chromatography on 
silica gel (hexane/EtOAc = 8/1 to 2/1) to yield the title compound as a pale yellow oil (913.3 mg, 97%). 
20
D][  = +49.3 (c = 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3): δ = 7.25 (dd, J = 9.2, 6.4 Hz, 1H), 6.19 (dd, J = 9.6, 
1.2 Hz, 1H), 6.01 (dd, J = 6.4, 1.2 Hz, 1H), 5.82-5.72 (m, 1H), 5.26-5.18 (m, 1H), 5.04-4.96 (m, 2H), 2.77-
2.66 (m, 2H), 2.39-2.30 (m, 4H), 1.30 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 172.2, 162.3, 
162.1, 143.3, 136.4, 115.5, 114.0, 104.3, 68.0, 40.0, 33.5, 28.7, 19.9. IR (film, cm-1): 3081, 2981, 2935, 
1723, 1637, 1558, 1365, 1170, 1086, 913, 797, 548. MS (EI): m/z (%) 236 (0.3), 153 (1.1), 136 (100), 108 
(42), 55 (32), 39 (8). HRMS (ESI): m/z: calcd for: C13H16O4Na [M+Na
+]: 259.09408, found: 259.09393.  
2-Allyl-4-bromothiazole (5). Anhydrous LiCl (16.9 mmol, 717 mg) was placed in a Schlenk tube under 
argon and was dried for 10 min at 300 oC (heat gun) in vacuum (2 × 10-3 mbar). Zinc 
powder (18.2 mmol, 1.19 g) was added and the mixture was dried again for 10 min at 
300 oC (heat gun) in vacuum (2 × 10-3 mbar). The flask was evacuated and refilled with 
argon twice before THF (15 mL) was introduced. The suspension was stirred at 50 oC when BrCH2CH2Br 
(0.56 mmol, 48 µL) was added to activate the Zn dust. The mixture was cooled to RT before Me3SiCl (0.23 
mmol, 28.5 µL) and 2,4-dibromothiazole (11.2 mmol, 2.73 g) were successively added and stirring was 
continued for 7 h. At this time, the resulting solution of the organozinc compound in THF was filtered 
through a pad of dry Celite (see General) under argon into a new dried and Ar-flushed Schlenk tube, 
rinsing the reaction vessel with THF (2 × 5 mL). The solution was cooled to 0 oC before allyl bromide (18.0 
mmol, 1.55 mL) was added, followed by CuCN (0.56 mmol, 50.3 mg). The mixture was stirred at 0 oC for 1 
h before the reaction was quenched with sat. aq. NH4Cl (20 mL). The mixture was diluted with Et2O (20 
mL), the aqueous layer was extracted with Et2O (3 × 20 mL). The combined organic phases were washed 
with sat. aq. NaCl, dried over MgSO4, filtered, and concentrated. The crude material was purified by flash 
chromatography on silica gel (pentane/Et2O = 250/1 to 50/1) to yield the title compound as a colorless 
oil (2.05 g, 89%). 1H NMR (400 MHz, CDCl3): δ = 7.12 (s, 1H), 6.01 (ddt, J = 17.2, 10.0, 7.2 Hz, 1H), 5.31-
5.24 (m, 2H), 3.76 (dt, J = 6.8, 1.6 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ = 170.6, 132.8, 124.4, 119.3, 
116.5, 37.8. IR (film, cm-1): 3122, 3083, 2981, 2904, 1640, 1477, 1250, 1076, 921, 834, 726. MS (EI): m/z 
(%) 204 (100), 179 (16), 138 (27), 124 (20), 97 (17), 80 (22), 57 (47). HRMS (ESI): m/z: calcd for: 
C6H6NBrSNa [M+Na




(S)-3-(4-Bromothiazol-2-yl)propane-1,2-diol (6). A pressure tube equipped with a magnetic stir bar was 
charged with Pt(dba)3 (0.065 mmol, 58.2 mg), ligand 8 (0.076 mmol, 68.8 mg), and 
B2(pin)2 (3.85 mmol, 978 mg). The tube was evacuated and refilled with argon. THF 
(2.8 mL) was added via syringe and the resulting solution stirred at 80 °C for 30 min. 
The tube was cooled to room temperature before compound 5 (2.75 mmol, 560.6 mg, freshly distilled 
before use) was introduced. The tube was sealed and stirring continued at 60 °C for 14 h. For work up, 
the mixture was cooled to RT and transferred into a 100 mL two-necked round bottom flask, rinsing with 
THF (2 × 2 mL). The mixture was cooled to 0 °C before aq. NaOH (3 M, 6.8 mL) was added, followed by 
dropwise addition of  hydrogen peroxide (30% w/w, 3.5 mL). The mixture was gradually warmed to room 
temperature and stirred for 4 h before the reaction was quenched at 0 °C by dropwise addition of sat. aq. 
sodium thiosulfate (2.8 mL) over 5 minutes. The mixture was diluted with ethyl acetate and aqueous 
layer extracted with ethyl acetate (6 × 20 mL). The combined extracts were dried over MgSO4, filtered, 
and concentrated, and the residue was purified by flash chromatography on silica gel (hexane/EtOAc = 
1/1 to 1/3, then EtOAc/MeOH = 25/1) to yield the title compound as a white solid (598 mg, 91%, 91% ee). 
[Conditions for HPLC analysis: Daicel Chiralpak IC-3 (4.6 mm × 150 mm), n-heptane/2-propanol = 80/20, v 
= 1.0 mL⋅min-1, λ = 250 nm, t (minor) = 8.02 min, t (major) = 5.81 min]; m.p. = 67.8-68.6 oC; 20
D][  = 13.0 
(c = 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3): δ = 7.13 (s, 1H), 4.19-4.13 (m, 1H), 3.74 (dd, J = 11.6, 4.0 Hz, 
1H), 3.66 (br. s, 1H), 3.60 (dd, J = 11.2, 6.0 Hz, 1H), 3.18 (d, J = 6.0 Hz, 2H), 2.67 (br. s, 1H). 13C NMR (100 
MHz, CDCl3): δ = 168.8, 124.3, 116.6, 70.8, 65.6, 36.6. IR (film, cm
-1): 3341, 3167, 3125, 3063, 2918, 2863, 
1477, 1256, 1072, 1035, 899, 624, 436. MS (EI): m/z (%) 239 (1.5), 208 (65), 179 (100), 138 (10), 99 (12). 
HRMS (ESI): m/z: calcd for: C6H8NO2BrSNa [M+Na
+]: 259.93515, found: 259.93503.  
 (S)-1-(4-Bromothiazol-2-yl)-3-((tert-butyldiphenylsilyl)oxy)propan-2-ol (7). TBDPSCl (3.70 mmol, 0.96 
mL) was added dropwise at 0 oC to a solution of compound 6 (3.25 mmol, 774 
mg), Et3N (9.75 mmol, 1.76 mL) and DMAP (0.33 mmol, 40 mg) in CH2Cl2 (33 mL). 
After stirring for 48 h, the reaction was quenched with water. The aqueous layer 
was extracted with ethyl acetate (3 × 20 mL) and the combined organic phases 
were dried over MgSO4, filtered, and concentrated. The crude material was purified by flash 
chromatography on silica gel (hexane/EtOAc = 15/1 to 6/1) to yield the title compound as a viscous 
yellow oil (1.54 g, quant.). 20
D][  = 6.2 (c = 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3): δ = 7.73-7.57 (m, 4H), 
7.49-7.33 (m, 6H), 7.11 (s, 1H), 4.21-4.08 (m, 1H), 3.70 (dd, J = 10.4, 4.8 Hz, 1H), 3.65 (dd, J = 10.0, 6.0 Hz, 
1H), 3.23 (dd, J = 15.2, 4.0 Hz, 1H), 3.13 (dd, J = 15.6, 8.4 Hz, 1H), 3.03 (d, J = 4.4 Hz, 1H), 1.07 (s, 9H). 13C 
NMR (100 MHz, CDCl3): δ = 168.6, 135.5, 132.82, 132.79, 129.9, 127.8, 124.2, 116.6, 70.9, 66.7, 37.0, 26.8, 
19.2. IR (film, cm-1): 3392, 3070, 3048, 2929, 2857, 1474, 1255, 1110, 1079, 739, 612, 503. MS (ESI): m/z: 
474 [M-H+]. HRMS (ESI): m/z: calcd for: C22H25NO2BrSSi [M-H
+]: 474.05643, found: 474.05645.  
Compound 16. 9-BBN (0.5 M in degassed THF, 9 mL) was added dropwise at 0 oC to a solution of 
compound 15 (3.44 mmol, 812.7 mg) in degassed THF (15 mL). The mixture 
was stirred for 6 h before degassed H2O (80 µL) was added and stirring 
continued for 15 min to quench the excess borane. In a second Schlenk tube, 
compound 7 (2.64 mmol, 1.258 g), RuPhos (0.264 mmol, 123.2 mg), Pd(OAc)2 
(0.135 mmol, 30.3 mg), and K3PO4 (8.45 mmol, 1.793 g) were dissolved in 
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degassed THF (8.6 mL). The mixture was vigorously stirred for 10 min before the borane solution was 
slowly added via canula (rinsing with 2 × 1 mL of THF). The resulting mixture was stirred at 50 oC for 30 
min before it was diluted with EtOAc (25 mL) and the reaction was quenched with H2O (10 mL). The 
aqueous layer was extracted with EtOAc (3 × 40 mL). The combined organic phases were washed with sat. 
aq. NaCl (20 mL), dried over MgSO4, filtered, and evaporated. The residue was purified by flash 
chromatography on silica gel (hexane/EtOAc = 8/1 to 1/1) to yield the title compound as a yellow oil 
(1.37 g, 82%). Small amounts of the isomeric product S1 were obtained as a yellow oil when the eluent 
was switched to hexane/EtOAc = 1/1 to 1/3. The ratio 16:S1 in the crude material was determined as 
88/12 by LC-MS analysis [50 × 3.0 mm Zorbax Eclipse Plus C18, 1.8μm, Nr USUYA03995, MeCN/H2O (0.1% 
TFA) = 60:40, v = 0.5 mL/min, λ = 228 nm, 35 °C, 120 bar]. 20
D][  = +15.3 (c = 1.0, CHCl3); 
1H NMR (400 
MHz, CDCl3): δ = 7.72-7.56 (m, 4H), 7.48-7.31 (m, 6H), 7.21 (dd, J = 9.6, 6.8 Hz, 1H), 6.75 (s, 1H), 6.15 (d, J 
= 9.2 Hz, 1H), 5.99 (d, J = 6.8 Hz, 1H), 5.27-5.16 (m, 1H), 4.17-4.10 (m, 1H), 3.84 (br s, 1H), 3.76-3.57 (m, 
2H), 3.22 (dd, J = 15.2, 3.6 Hz, 1H), 3.11 (dd, J = 15.2, 8.0 Hz, 1H), 2.78-2.60 (m, 4H), 2.29 (t, J = 7.2 Hz, 
2H), 1.72-1.54 (m, 4H), 1.30 (d, J = 6.4 Hz, 3H), 1.06 (s, 9H). 13C NMR (100 MHz, CDCl3): δ = 172.7, 167.0, 
162.2, 162.1, 156.4, 143.2, 135.5, 133.0, 129.7, 127.7, 114.0, 112.4, 104.3, 71.1, 67.9, 66.7, 40.1, 36.4, 
34.1, 31.0, 28.4, 26.8, 24.4, 19.9, 19.2. IR (film, cm-1): 3430, 3071, 2930, 2857, 1730, 1636, 1558, 1427, 
1110, 1079, 1059, 799, 702, 504. MS (ESI): m/z: 656 [M+Na+]. HRMS (ESI): m/z: calcd for: C35H43NO6SSiNa 
[M+Na+]: 656.24726, found: 656.24715.  
Isomer S1. 20
D][  = +32.7 (c = 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3): δ = 7.66-7.64 (m, 4H), 7.46-7.35 (m, 
6H), 7.21 (dd, J = 9.2, 6.4 Hz, 1H), 6.73 (s, 1H), 6.16 (dd, J = 9.2, 0.8 Hz, 1H), 5.99 (dd, 
J = 6.8, 0.8 Hz, 1H), 5.25-5.17 (m, 1H), 4.26-4.09 (m, 1H), 3.56-3.37 (m, 2H), 3.19-
3.10 (m, 2H), 2.78-2.63 (m, 4H), 2.29 (t, J = 7.2 Hz, 2H), 1.69-1.58 (m, 5H), 1.30 (d, J 
= 6.4 Hz, 3H), 1.04 (s, 9H). 13C NMR (100 MHz, CDCl3): δ = 172.7, 165.9, 162.2, 156.4, 
143.2, 135.8, 135.7, 133.6, 133.4, 129.9, 127.8, 127.7, 114.0, 112.9, 104.3, 72.5, 
68.0, 65.3, 40.1, 37.6, 34.1, 30.9, 28.5, 26.9, 24.4, 19.9, 19.2. IR (film, cm-1): 3429, 
3071, 2930, 2856, 1730, 1636, 1558, 1427, 1105, 1056, 799, 702, 505. MS (ESI): m/z: 656 [M+Na+]. HRMS 
(ESI): m/z: calcd for: C35H43NO6SSiNa [M+Na
+]: 656.24726, found: 656.24735.  
Seco-Acid 17. MeMgBr (0.56 M in Et2O, 1.8 mL) was added via syringe pump over 76 min to a solution of 
Fe(acac)3 (0.035 mmol, 12.4 mg) and compound 16 (0.122 mmol, 77.0 mg) 
in Et2O/cyclopentyl methyl ether (1/1, 4.8 mL) at 30 
oC. Stirring was 
continued for 140 min at this temperature before the reaction was 
quenched with aq. sat. NH4Cl and the pH of the aqueous layer was 
adjusted to 2-3 upon addition of aq. HCl (1 M). The aqueous layer was 
extracted with EtOAc (5 × 25 mL) and the combined organic layers were 
washed with sat. aq. NaCl, dried over MgSO4, filtered and concentrated to an oily residue, which was 
purified by preparative TLC (hexane/EtOAc = 1/1) to yield the title compound as a yellow oil (59 mg, 75%). 
[Conditions for LC-MS analysis: 2.1 × 150 mm YMC-Pack Pro C18 S-5 μm, MeCN/H2O (0.1% TFA) = 70:30, 
v = 0.2 mL/min, λ = 228 nm, 35 °C, 40 bar]; 20
D][  = 52.2 (c = 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3): δ = 
7.66-7.64 (m, 4H), 7.48-7.32 (m, 6H), 7.15 (d, J = 12.0 Hz, 1H), 6.86 (t, J = 11.6 Hz, 1H), 6.76 (s, 1H), 5.59 
(d, J = 11.6 Hz, 1H), 5.71-4.98 (br s, 1H), 5.16-5.08 (m, 1H), 4.18-4.12 (m, 1H), 3.75-3.53 (m, 3H), 3.26 (dd, 
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J = 11.2, 3.2 Hz, 1H), 3.15 (dd, J = 15.2, 8.4 Hz, 1H), 2.81-2.61 (m, 2H), 2.44 (dd, J = 14.4, 8.8 Hz, 1H), 2.35-
2.23 (m, 3H), 1.87 (s, 3H), 1.72-1.57 (m, 4H), 1.24 (d, J = 6.4 Hz, 3H), 1.06 (s, 9H). 13C NMR (100 MHz, 
CDCl3): δ = 173.1, 170.4, 167.6, 156.3, 145.3, 140.6, 135.5, 133.1, 133.0, 129.8, 127.7, 124.1, 116.1, 112.6, 
71.2, 68.3, 66.7, 46.8, 36.3, 34.2, 30.6, 28.7, 26.8, 24.2, 20.2, 19.2, 17.2. IR (film, cm-1): 3433, 3070, 2932, 
2858, 1728, 1632, 1428, 1111, 828, 701, 503. MS (ESI): m/z: 672 [M+Na+]. HRMS (ESI): m/z: calcd for: 
C36H47NO6SSiNa [M+Na
+]: 672.27856, found: 672.27890.  
Compound 19. 2-Bromo-1-ethyl-pyridinium tetrafluoroborate (6.4 mmol, 1.75 g) was added to a solution 
of compound 17 (0.26 mmol, 166.2 mg) and NaHCO3 (63.9 mmol, 5.37 g) 
in CH2Cl2 (470 mL). The mixture was stirred for 45 h in the dark. The 
reaction was quenched with H2O (50 mL), the aqueous layer was 
extracted with tert-butyl methyl ether (4 × 50 mL) and the combined 
organic phases were dried over MgSO4, filtered, and evaporated. The 
residue was purified by flash chromatography on silica gel (hexane/Et2O = 
8/1 to 3/1) to yield the title compound as a colorless oil (114.3 mg, 71%). 
20
D][  = 211.3 (c = 1.0, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.72-7.58 (m, 4H), 7.48-7.33 (m, 6H), 7.00 
(d, J = 12.0 Hz, 1H), 6.70 (s, 1H), 6.69 (t, J = 11.5 Hz, 1H), 5.66-5.49 (m, 1H), 5.41 (d, J = 11.5 Hz, 1H), 5.21-
5.06 (m, 1H), 3.83 (dd, J = 11.0, 5.0 Hz, 1H), 3.77 (d, J = 10.5, 4.5 Hz, 1H), 3.31 (dd, J = 14.5, 3.0 Hz, 1H), 
3.23 (dd, J = 14.5, 11.5 Hz, 1H), 2.83 (dddd, J = 15.5, 6.0, 4.5, 1.5 Hz, 1H), 2.59 (ddd, J = 14.5, 10.0, 4.5 Hz, 
1H), 2.39-2.23 (m, 2H), 2.22-2.08 (m, 2H), 1.83 (s, 3H), 1.82-1.78 (m, 1H),1.72-1.65 (m, 1H), 1.41-1.32 (m, 
1H), 1.30-1.24 (m, 1H), 1.24 (d, J = 6.0 Hz, 3H), 1.07 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 173.2, 165.9, 
164.7, 156.4, 145.5, 140.9, 135.6, 135.5, 133.13, 133.11, 129.7, 127.72, 127.69, 124.0, 114.8, 113.3, 72.3, 
67.1, 65.4, 48.2, 35.0, 34.7, 30.7, 28.1, 26.8, 23.2, 21.2, 19.3, 16.7. IR (film, cm-1): 3071, 2931, 2857, 1719, 
1632, 1427, 1161, 1112, 814, 731, 701, 504. MS (ESI): m/z: 654 [M+Na+]. HRMS (ESI): m/z: calcd for: 
C36H45NO5SSiNa [M+Na
+]: 654.26799, found: 654.26771.  
Scalable Procedure for the Preparation of 19. MeMgBr (0.56 M in Et2O, 6.06 mL) was added via syringe 
pump over 3.5 h to a solution of Fe(acac)3 (0.12 mmol, 42.8 mg) and compound 16 (0.40 mmol, 256.1 mg) 
in Et2O/cyclopentyl methyl ether (1/1, 16.2 mL) at 30 
oC. Stirring was continued for 2.5 h at this 
temperature before the reaction was quenched with aq. sat. NH4Cl and the pH of the aqueous layer was 
adjusted to 2-3 upon addition of aq. HCl (1 M). The aqueous phase was extracted with EtOAc (5 × 30 mL). 
The combined organic layers were washed with sat. aq. NaCl, dried over MgSO4, filtered and 
concentrated to an oily residue, which was dried in high vacuum for 1 h. This crude material was directly 
used in the next step.  
2-Bromo-1-ethyl-pyridinium tetrafluoroborate (9.95 mmol, 2.73 g) was added to a solution of the crude 
material and NaHCO3 (103.3 mmol, 8.68 g) in CH2Cl2 (680 mL). The mixture was stirred for 43 h in the 
dark before the reaction was quenched with H2O (80 mL). The aqueous layer was extracted with tert-
butyl methyl ether (4 × 70 mL), and the combined organic phases were dried over MgSO4, filtered, and 
evaporated. The residue was purified by flash chromatography on silica gel (hexane/Et2O = 8/1 to 3/1) to 
yield the title compound as a colorless oil (139 mg, 55%). Unreacted starting material 16 was recovered 
in 14% yield (34.8 mg) when the eluent was switched to hexane/EtOAc = 2/1 to 1/1. 
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Compound 20. TBAF (0.42 mmol, 1 M in THF, 0.42 mL) was slowly added to a solution of compound 19 
(0.21 mmol, 131.9 mg) in THF (3 mL) and acetic acid (1.02 mmol, 58.7 µL). After 
stirring for 16 h, the mixture was poured into a mixed solution of ethyl acetate 
(5 mL) and sat. aq. NaHCO3 (5 mL). The aqueous layer was extracted with ethyl 
acetate (5 × 10 mL), and the combined organic phases were dried over MgSO4, 
filtered, and concentrated by rotary evaporation. The crude material was 
purified by flash column chromatography on silica gel (hexane/EtOAc = 2/1 to 
1/2) to yield the title compound as a colorless oil (82.1 mg, quant.). 20
D][  = 
273.5 (c = 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 6.97 (d, J = 11.6 Hz, 1H), 6.69 (t, J = 11.6 Hz, 1H),  
6.68 (s, 1H), 5.59-5.46 (m, 1H), 5.40 (d, J = 11.2 Hz, 1H), 5.19-5.05 (m, 1H), 3.89-3.70 (m, 2H), 3.27-3.19 
(m, 2H), 2.82 (dt, J = 14.4, 4.8 Hz, 1H), 2.62-2.51 (m, 1H), 2.45 (br s, 1H), 2.36-2.21 (m, 2H), 2.19-2.10 (m, 
2H), 1.82 (s, 3H), 1.80-1.72 (m, 1H), 1.69-1.60 (m, 1H), 1.40-1.13 (m, 1H), 1.26-1.14 (m, 1H), 1.23 (d, J = 
6.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ 173.2, 165.7, 165.0, 156.4, 146.1, 141.4, 123.9, 114.3, 113.3, 
73.0, 67.1, 64.5, 48.2, 34.6, 34.5, 30.6, 28.0, 23.1, 21.1, 16.8. IR (film, cm-1): 3308, 2931, 2868, 1714, 1631, 
1427, 1201, 1155, 1048, 814, 750. MS (ESI): m/z: 416 [M+Na+]. HRMS (ESI): m/z: calcd for: C20H27NO5SNa 
[M+Na+]: 416.15022, found: 416.15025.  
 Compound 21. Sulfur trioxide pyridine complex (0.301 mmol, 47.9 mg) and anhydrous iPr2NEt (0.74 
mmol, 128.2 µL) were successively added to a solution of compound 20 
(0.104 mmol, 40.8 mg) in CH2Cl2 (1.6 mL) at 20 
oC. The resulting mixture 
was stirred for 5 min before anhydrous DMSO (1.05 mmol, 74 µL) was added 
dropwise. Stirring was continued for 40 min at 20 oC before the solution 
was poured into a mixture of tert-butyl methyl ether (10 mL) and aq. 
phosphate buffer (pH 7, 10 mL). The aqueous layer was extracted with tert-
butyl methyl ether (3 × 15 mL) and the combined organic phases were 
washed with phosphate buffer, dried over MgSO4, filtered, and concentrated by rotary evaporation to an 
oily residue, which was dried in vacuum for 2 h (2 × 10-3 mbar). The crude material was directly used in 
the next step.  
2-(Triphenylphosphoranylidene)-propionaldehyde (0.13 mmol, 39.9 mg) was added to a solution of the 
crude product in toluene (5 mL) and the resulting solution was stirred at 80 oC for 2 h. Once the reaction 
was complete (monitored by TLC), the mixture was allowed to reach ambient temperature before the 
reaction was quenched by H2O (5 mL). The aqueous layer was extracted with tert-butyl methyl ether (4 × 
10 mL) and the combined extracts were dried over MgSO4, filtered, and concentrated. The residue was 
purified by flash chromatography on silica gel (hexane/Et2O = 8/1 to 2/3) to yield the title compound  as 
a white solid (38.6 mg, 86%). 20
D][  = 320.3 (c = 1.0, CHCl3); m.p. = 134.7-135.8 
oC; 1H NMR (400 MHz, 
CDCl3): δ = 9.46 (s, 1H), 6.97 (d, J = 12.0 Hz, 1H), 6.72 (s, 1H), 6.71 (dd, J = 12.0, 11.2 Hz, 1H), 6.49-6.26 (m, 
2H), 5.36 (d, J = 11.2 Hz, 1H), 5.16-5.08 (m, 1H), 3.24-3.19 (m, 2H), 2.85 (dt, J = 14.4, 4.8 Hz, 1H), 2.57 
(ddd, J = 14.8, 10.4, 4.4 Hz, 1H), 2.41-2.05 (m, 4H), 1.96 (d, J = 1.2 Hz, 3H), 1.87-1.78 (m, 1H), 1.83 (s, 3H), 
1.71-1.51 (m, 1H), 1.42-1.35 (m, 1H), 1.24-1.17 (m, 1H), 1.21 (d, J = 6.4 Hz, 3H). 13C NMR (75 MHz, CDCl3): 
δ = 194.4, 173.0, 164.3, 163.9, 156.9, 147.8, 146.5, 141.7, 140.7, 123.8, 113.9, 113.5, 68.5, 67.1, 48.3, 
37.3, 34.6, 30.7, 28.0, 23.1, 21.1, 16.8, 9.9. IR (film, cm-1): 2964, 2931, 2857, 1713, 1687, 1651, 1424, 
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1144, 1114, 812, 752. MS (ESI): m/z: 432 [M+H+]. HRMS (ESI): m/z: calcd for: C23H30NO5S [M+H
+]: 
432.18392, found: 432.18422.  
Compound 22. A mixture of CHI3 (0.42 mmol, 166 mg) and compound 21 (61.6 µmol, 26.6 mg) in 
degassed THF (1.4 mL, rinsing the flask with 2 × 0.5 mL of THF) was added 
dropwise to a slurry of CrCl2·1.05 THF (1.65 mmol, 322 mg) in degassed 
THF (1.5 mL) at 0 oC. The mixture was stirred at this temperature for 1.5 h. 
Once the reaction was complete (monitored by TLC), the mixture was 
diluted with tert-butyl methyl ether (5 mL) and H2O (5 mL). The aqueous 
layer was extracted with tert-butyl methyl ether (3 × 10 mL) and the 
combined extracts were dried over MgSO4, filtered, and evaporated. The 
crude material was purified by flash chromatography on silica (hexane/Et2O = 10/1 to 2/1) to yield the 
title compound as a yellow oil (31.2 mg, 91%, product/ of isomers = 94/6) [Conditions for LC-MS 
analysis: 2.1 × 150 mm YMC-Pack Pro C18 S-5 μm, MeOH/H2O = 90:10, v = 0.2 mL/min, λ = 228 nm, 35 °C, 
64 bar]; 20
D][  = 412.7 (c = 1.0, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.06 (d, J = 14.5 Hz, 1H), 6.99 (d, J 
= 12.0 Hz, 1H), 6.99 (s, 1H), 6.67 (t, J = 11.5 Hz, 1H), 6.44 (d, J = 14.5 Hz, 1H), 6.20 (td, J = 9.0, 5.0 Hz, 1H), 
5.48 (d, J = 8.5 Hz, 1H), 5.34 (d, J = 11.0 Hz, 1H), 5.20-5.03 (m, 1H), 3.19-3.12 (m, 2H), 2.85 (dt, J = 14.5, 
5.0 Hz, 1H), 2.58 (ddd, J = 15.0, 10.5, 4.5 Hz, 1H), 2.37- 2.24 (m, 2H), 2.22-2.06 (m, 2H), 1.95 (s, 3H), 1.88-
1.79 (m, 1H), 1.83 (s, 3H), 1.70-1.63 (m, 1H), 1.41-1.34 (m, 1H), 1.23 (d, J = 8.5 Hz, 3H), 0.95-0.79 (m, 1H). 
13C NMR (75 MHz, CDCl3): δ = 173.1, 164.9, 164.4, 156.7, 148.5, 145.8, 141.0, 138.0, 129.9, 123.9, 114.6, 
113.3, 77.6, 68.6, 67.1, 48.3, 38.4, 34.7, 30.8, 28.1, 23.2, 21.2, 16.8, 12.8. IR (film, cm-1): 2975, 2930, 2856, 
1714, 1631, 1427, 1152, 1116, 860, 751. MS (EI): m/z (%) 555 (49), 428 (100), 305 (12), 276 (22), 258 (12), 
250 (18), 232 (14), 199 (15), 135 (47), 107 (33), 91 (22), 79 (18). HRMS (ESI): m/z: calcd for: 
C24H30NO4SINa [M+Na
+]: 578.08325, found: 578.08409. 
DMDA-Pat A (2). Flame-dried [Ph2PO2
-][NBu4
+] (0.089 mmol, 41.0 mg) was dissolved in degassed DMF 
(0.3 mL) and the resulting solution was added to a Schlenk tube 
containing compound 22 (0.045 mmol, 25.0 mg) (rinsing with 2 × 
0.15 mL DMF). (E)-N,N-Dimethyl-3-(tributylstannyl)but-2-en-1-
amine (23)[3] (0.072 mmol, 28.0 mg)  and copper thiophene 
carboxylate (CuTC, 0.068 mmol, 12.9 mg) were then introduced, 
followed by Pd(PPh3)4 (0.0045 mmol, 5.2 mg). The resulting 
mixture was stirred for 1 h before the reaction was quenched 
with water (5 mL). After dilution with EtOAc (5 mL), the aqueous 
layer was extracted with EtOAc (3 × 10 mL). The combined extracts were washed with sat. aq. NaCl, dried 
over MgSO4, filtered, and evaporated. The residue was purified by flash chromatography on silica 
(pretreated with 1% Et3N in hexane, hexane/EtOAc = 1/1 then EtOAc/Et3N = 120/1 to 50/1) to yield the 
title compound as a yellow oil (19.7 mg, 83%). 20
D][  = 379.7 (c = 1.0, CHCl3); 
1H NMR (400 MHz, C6D6): δ 
= 7.47 (d, J = 11.8 Hz, 1H), 6.70 (ddd, J = 9.1, 8.7, 5.6 Hz, 1H), 6.47 (dd, J = 11.8, 11.4 Hz, 1H), 6.32 (d, J = 
15.9 Hz, 1H), 6.21 (d, J = 15.9 Hz, 1H), 6.20 (d, J = 0.8 Hz, 1H), 5.69 (t, J = 6.8 Hz, 1H), 5.55 (d, J = 11.4 Hz, 
1H), 5.50 (dd, J = 9.1, 1.1 Hz, 1H), 5.15 (dqd, J = 10.9, 6.4, 1.6 Hz, 1H), 3.07 (dd, J = 14.5, 5.6 Hz, 1H), 3.06 
(dd, J = 14.5, 8.7 Hz, 1H), 2.93 (d, J = 6.8 Hz, 2H), 2.78 (dt, J = 14.4, 4.0 Hz, 1H), 2.45 (ddd, J = 16.3, 10.3, 
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6.5 Hz, 1H), 2.35 (ddd, J = 4.0, 10.5, 14.3 Hz, 1H), 2.17-2.02 (m, 3H), 2.12 (s, 6H), 1.91 (d, J = 1.1 Hz, 3H), 
1.71 (s, 3H), 1.65 (dd, J = 12.9, 1.6 Hz, 1H), 1.57-1.43 (m, 3H), 1.55 (s, 3H), 0.96 (d, J = 6.4 Hz, 3H). 13C 
NMR (100 MHz, CDCl3): δ = 172.5, 165.2, 164.9, 157.4, 145.6, 141.3, 138.4, 135.9, 134.3, 131.5, 131.2, 
129.3, 124.6, 115.5, 113.1, 69.8, 66.8, 57.6, 48.5, 45.5, 39.0, 35.0, 31.2, 28.5, 23.7, 21.2, 16.7, 13.3, 12.9. 
IR (film, cm-1): 2973, 2932, 2856, 2814, 2764, 1729, 1713, 1631, 1427, 1154, 1112, 814, 750, 539. MS 
(ESI): m/z: 527 [M+H+]. HRMS (ESI): m/z: calcd for: C30H43N2O4S [M+H
+]: 527.29381, found: 527.29421. 
 






Table S-1. Signal assignment for DMDA-Pat A (2); arbitrary numbering scheme as shown in the Insert 
Position 13C NMR,  (ppm) 1H NMR,  (ppm) 
10 172.5 - 
17 165.2 - 
1 164.9 - 
15 157.4 - 
5 145.6 - 
3 141.3 6.47 
21 138.4 - 
24 135.9 - 
23 134.3 6.32 
25 131.5 5.69 
22 131.2 6.21 
20 129.3 5.50 
4 124.6 7.47 
2 115.5 5.55 
16 113.1 6.20 
19 69.8 6.70 
7 66.8 5.15 
26 57.6 2.93 
6 48.5 2.09, 1.65 
29, 30 45.5 2.12 
18 39.0 3.07, 3.06 
11 35.0 2.45, 2.13 
14 31.2 2.78, 2.35 
13 28.5 2.06, 1.53 
12 23.7 1.50, 1.48 
9 21.2 0.96 
8 16.7 1.55 
27 13.3 1.91 





Table S-2. Comparison of the 1H NMR data of DMDA-Pat A (2) (ca. 15 mg in 0.5 mL of C6D6) with those 
reported in the literature 
Literature[4] This work  
δ (ppm) J (Hz) δ (ppm) J (Hz) Δδ (ppm) 
7.47 12.0 7.47 11.8 0 
6.71 5.0, 9.0 6.70 5.6, 8.7, 9.1 0.01 
6.45 11.5 6.47 11.4, 11.8 0.02 
6.32 16.0 6.32 15.9 0 
6.21 16.0 6.21 15.9 0 
6.17 - 6.20 0.8 0.03 
5.69 7.0 5.69 6.8 0 
5.55 11.5 5.55 11.4 0 
5.49 9.0 5.50 1.1, 9.1 0.01 
5.19-5.11 - 5.15 1.6, 6.4, 10.9 - 
3.08-3.01 - 
3.07 5.6, 14.5 - 
3.06 8.7, 14.5 - 
2.91 6.5 2.93 6.8 0.02 
2.78 4.5, 14.0 2.78 4.0, 14.4 0 
2.48-2.42 - 2.45 6.5, 10.3, 16.3 - 
2.33 4.0, 10.0, 14.5 2.35 4.0, 10.5, 14.3 0.02 
2.11 - 2.12 - 0.01 
2.16-2.03 - 2.17-2.02 - 0.01 
1.90 1.0 1.91 1.1 0.01 
1.71 - 1.71 - 0 
1.64-1.61 - 1.65 1.6, 12.9 - 
1.56-1.43 - 1.57-1.43 - 0.01 
1.54 - 1.55 - 0.01 
0.96-0.81 - - - - 





Table S-3. Comparison of the 13C NMR data of DMDA-Pat A (2) in C6D6 (ca. 15 mg in 0.5 mL of C6D6) with 






172.5 172.5 0 
165.2 165.2 0 
164.9 164.9 0 
157.4 157.4 0 
145.9 145.6 0.3 
141.4 141.3 0.1 
138.1 138.4 0.3 
133.8 135.9 2.1 
133.1 134.3 1.2 
130.8 131.5 0.7 
- 131.2 - 
126.9 129.3 2.4 
124.6 124.6 0 
122.1 - - 
115.3 115.5 0.2 
113.2 113.1 0.1 
69.7 69.8 0.1 
66.8 66.8 0 
55.1 57.6 2.5 
48.5 48.5 0 
42.3 45.5 3.2 
38.9 39.0 0.1 
35.0 35.0 0 
31.2 31.2 0 
30.2 - - 
28.5 28.5 0 
23.7 23.7 0 
21.2 21.2 0 
16.7 16.7 0 
13.4 13.3 0.1 






[1] N.-W. Tseng, M. Lautens, J. Org. Chem. 2009, 74, 2521-2526. 
[2] T.-Y. Yuen, M. A. Brimble, Org. Lett. 2012, 14, 5154-5157. 
[3] a) L. Otero, B. Vaz, R. Álvarez, Á. R. de Lera, Chem. Commun. 2013, 49, 5043-5045; b) G. Pattenden, D. 
J. Critcher, M. Remuiñán, Can. J. Chem. 2004, 82, 353-365. 
[4] D. Romo, N. S. Choi, S. Li, I. Buchler, Z. Shi, J. O. Liu, J. Am. Chem. Soc. 2004, 126, 10582-10588. 
[5] W.-K. Low, J. Li, M. Zhu, S. S. Kommaraju, J. Shah-Mittal, K. Hull, J. O. Liu, D. Romo, Bioorg. Med. Chem. 





























































Comparison of Romo’s 13C NMR (top) and Fürstner’s (bottom)
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